Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.

Song, Geng; Zhang, Fei-Fei; Cheng, Huai-Dong

Song, Geng; Zhang, Fei-Fei; Cheng, Huai-Dong.

Afiliación

Song G; Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhang FF; Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Cheng HD; Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.

Australas J Dermatol ; 63(2): 217-221, 2022 May.

Article en En | MEDLINE | ID: mdl-35229882

Asunto(s)

Anticuerpos Monoclonales Humanizados; Talidomida; Anticuerpos Monoclonales Humanizados/efectos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Proliferación Celular; Humanos; Talidomida/efectos adversos

Palabras clave

camrelizumab; reactive cutaneous capillary endothelial proliferation; thalidomide

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talidomida / Anticuerpos Monoclonales Humanizados Límite: Humans Idioma: En Revista: Australas J Dermatol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google